Genomewide Association Studies and Common Disease — Realizing Clinical Utility
- 20 December 2012
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 367 (25), 2370-2371
- https://doi.org/10.1056/nejmp1212285
Abstract
The value of GWAS for finding therapies for complex disease may seem dubious. But even if genetic variants confer modest risk and subtly alter biologic function, drugs mimicking their activity can have much more powerful effects. GWAS data analysis could identify key leads.Keywords
This publication has 5 references indexed in Scilit:
- Novel systemic drugs under investigation for the treatment of psoriasisJournal of the American Academy of Dermatology, 2012
- TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosisNature, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Treating Human Autoimmunity: Current Practice and Future ProspectsScience Translational Medicine, 2012
- Type 2 diabetes and obesity: genomics and the clinicHuman Genetics, 2011